Abstract
Norepinephrine is considered to mediate the cardiomyocyte hypertrophic response through α1-adrenoceptor activation of phospholipase C (PLC). However, the regulation of specific PLC isozyme gene and protein expression as well as activities in normal and hypertrophied myocardium is not completely defined. In this chapter, we provide an overview of the role of PLC-mediated signal transduction pathways in cardiac hypertrophy. We also identify some of the mechanisms that might be involved in the regulation of PLC isozyme gene expression, protein abundance, and activities. While PLC has a key role in cardiomyocyte hypertrophy, the evidence provided here suggests that PLC activities regulate their own gene expression that perpetuates the hypertrophic signal to produce a rapid progression of cardiac hypertrophy and ultimate transition to heart failure.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Dhalla NS, Heyliger CE, Beamish RE et al (1987) Pathophysiological aspects of myocardial hypertrophy. Can J Cardiol 3:183–196
Hefti MA, Harder BA, Eppenberger HM, Schaub MC (1997) Signaling pathways in cardiac myocyte hypertrophy. J Mol Cell Cardiol 29:2873–2892
Jaffre F, Callebert J, Sarre A et al (2004) Involvement of the serotonin 5-HT2B receptor in cardiac hypertrophy linked to sympathetic stimulation: control of interleukin-6, interleukin-1β, and tumor necrosis factor-α cytokine production by ventricular fibroblasts. Circulation 110:969–974
Nishikawa K, Yoshida M, Kusuhara M et al (2006) Left ventricular hypertrophy in mice with a cardiac-specific overexpression of interleukin-1. Am J Physiol Heart Circ Physiol 291:H176–H183
Schmidt BM, Schmieder RE (2005) Cardiotrophin: its importance as a pathogenetic factor and as a measure of left ventricular hypertrophy. J Hypertens 23:2151–2153
Ponten A, Li X, Thoren P et al (2003) Transgenic overexpression of platelet-derived growth factor-C in the mouse heart induces cardiac fibrosis, hypertrophy, and dilated cardiomyopathy. Am J Pathol 163:673–682
Cheng TH, Shih NL, Chen CH et al (2005) Role of mitogen-activated protein kinase pathway in reactive oxygen species-mediated endothelin-1-induced beta-myosin heavy chain gene expression and cardiomyocyte hypertrophy. J Biomed Sci 12:123–133
Schnabel P, Mies F, Nohr T, Geisler M, Bohm M (2000) Differential regulation of phospholipase C-β isozymes in cardiomyocyte hypertrophy. Biochem Biophys Res Commun 275:1–6
Ganguly PK, Lee SL, Beamish RE, Dhalla NS (1989) Altered sympathetic and adrenoceptors during the development of cardiac hypertrophy. Am Heart J 118:520–525
Ruzicka M, Leenen FH (1995) Relevance of blockade of cardiac and circulatory angiotensin-converting enzyme for the prevention of volume overload-induced cardiac hypertrophy. Circulation 91:16–19
Lear W, Ruzicka M, Leenen FH (1997) ACE inhibitors and cardiac ACE mRNA in volume overload-induced cardiac hypertrophy. Am J Physiol Heart Circ Physiol 273:H641–H646
Zhao W, Ahokas RA, Weber KT, Sun Y (2006) ANG-II-induced cardiac molecular and cellular events: role of aldosterone. Am J Physiol Heart Circ Physiol 29:H336–H343
Jesmin S, Zaedi S, Maeda S et al (2006) Endothelin antagonism suppresses plasma and cardiac endothelin-1 levels in SHRSPs at the typical hypertensive stage. Exp Biol Med 231:919–924
Cernacek P, Stewart DJ, Monge JC, Rouleau JL (2003) The endothelin system and its role in acute myocardial infarction. Can J Physiol Pharmacol 81:598–606
Chien KR, Knowlton KU, Zhu H, Chien S (1991) Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response. FASEB J 5:3037–3046
Tappia PS, Singal T, Dent MR et al (2006) Phospholipid-mediated signaling in diseased myocardium. Future Lipidol 1:701–717
Tappia PS, Dent MR, Dhalla NS (2006) Oxidative stress and redox regulation of phospholipase D in myocardial disease. Free Radic Biol Med 41:349–361
Tappia PS (2007) Phospholipid-mediated signaling systems as novel targets for treatment of heart disease. Can J Physiol Pharmacol 85:25–41
Rhee SG (2001) Regulation of phosphoinositide-specific phospholipase C. Annu Rev Biochem 70:281–312
Singal T, Dhalla NS, Tappia PS (2004) Phospholipase C may be involved in norepinephrine-induced cardiac hypertrophy. Biochem Biophys Res Commun 320:1015–1019
Singal T, Dhalla NS, Tappia PS (2006) Norepinephrine-induced changes in gene expression of phospholipase C in cardiomyocytes. J Mol Cell Cardiol 41:126–137
Tappia PS, Padua RR, Panagia V, Kardami E (1999) Fibroblast growth factor-2 stimulates phospholipase C β in adult cardiomyocytes. Biochem Cell Biol 77:569–575
Guo Y, Rebecchi M, Scariata S (2005) Phospholipase C β2 binds to and inhibits phospholipase C δ1. J Biol Chem 280:1438–1447
Fukami K (2002) Structure, regulation, and function of phospholipase C isozymes. J Biochem 131:293–299
James SR, Downes CP (1997) Structural and mechanistic features of phospholipases C: effectors of inositol phospholipid-mediated signal transduction. Cell Signal 9:329–336
Lopez I, Mak EC, Ding J et al (2001) A novel bifunctional phospholipase C that is regulated by Gα12 and stimulates the Ras/mitogen-activated protein kinase pathway. J Biol Chem 276:2758–2765
Heredia Mdel P, Delgado C, Pereira L et al (2005) Neuropeptide Y rapidly enhances [Ca2+]i transients and Ca2+ sparks in adult rat ventricular myocytes through Y1 receptor and PLC activation. J Mol Cell Cardiol 38:205–212
Balogh J, Wihlborg AK, Isackson H et al (2005) Phospholipase C and cAMP-dependent positive inotropic effects of ATP in mouse cardiomyocytes via P2Y11-like receptors. J Mol Cell Cardiol 39:223–230
Yin G, Yan C, Berk BC (2003) Angiotensin II signaling pathways mediated by tyrosine kinases. Int J Biochem Cell Biol 35:780–783
Rebecchi MJ, Pentyala SN (2000) Structure, function, and control of phosphoinositide-specific phospholipase C. Physiol Rev 80:1291–1335
Song C, Hu CD, Masago M et al (2001) Regulation of a novel human phospholipase C, PLCε, through membrane targeting by Ras. J Biol Chem 276:2752–2757
Saunders CM, Larman MG, Parrington J et al (2002) PLC ζ: a sperm-specific trigger of Ca2+ oscillations in eggs and embryo development. Development 129:3533–3544
Wing MR, Bourdon DM, Harden TK (2003) PLC-ε: a shared effector protein in Ras-, Rho-, and G αβγ-mediated signaling. Mol Interv 3:273–280
Hwang JI, Oh YS, Shin KJ et al (2005) Molecular cloning and characterization of a novel phospholipase C, PLC-η. Biochem J 389:181–186
Tappia PS, Liu S-Y, Shatadal S et al (1999) Changes in sarcolemmal PLC isoenzymes in postinfarct congestive heart failure: partial correction by imidapril. Am J Physiol Heart Circ Physiol 277:H40–H49
Wolf RA (1992) Association of phospholipase C-δ with a highly enriched preparation of canine sarcolemma. Am J Physiol Cell Physiol 263:C1021–C1028
Wang H, Oestreich EA, Maekawa N et al (2005) Phospholipase C ε modulates β-adrenergic receptor-dependent cardiac contraction and inhibits cardiac hypertrophy. Circ Res 97:1305–1313
Asemu G, Dhalla NS, Tappia PS (2004) Inhibition of PLC improves postischemic recovery in isolated rat heart. Am J Physiol Heart Circ Physiol 287:H2598–H2605
Newton AC, Johnson JE (1998) Protein kinase C: a paradigm for regulation of protein function by two membrane-targeting modules. Biochim Biophys Acta 1376:155–172
Malhotra A, Kang BP, Opawumi D et al (2001) Molecular biology of protein kinase C signaling in cardiac myocytes. Mol Cell Biochem 225:97–107
Kamp TJ, Hell JW (2000) Regulation of cardiac L-type calcium channels by protein kinase A and protein kinase C. Circ Res 87:1095–1102
Churchill E, Budas G, Vallentin A et al (2008) PKC isozymes in chronic cardiac disease: possible therapeutic targets? Annu Rev Pharmacol Toxicol 48:569–599
Dorn GW II, Force T (2005) Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 115:527–537
Sabri A, Steinberg SF (2003) Protein kinase C isoform-selective signals that lead to cardiac hypertrophy and the progression of heart failure. Mol Cell Biochem 251:97–101
Kockskämper J, Zima AV, Roderick HL et al (2008) Emerging roles of inositol 1,4,5-trisphosphate signaling in cardiac myocytes. J Mol Cell Cardiol 45:128–147
Vasilevski O, Grubb DR, Filtz TM et al (2008) Ins(1,4,5)P3 regulates phospholipase C β1 expression in cardiomyocytes. J Mol Cell Cardiol 45:679–684
Wu X, Zhang T, Bossuyt J et al (2006) Local InsP3-dependent perinuclear Ca2+ signaling in cardiac myocyte excitation-transcription coupling. J Clin Invest 116:675–682
Bers DM (2002) Cardiac excitation-contraction coupling. Nature 415:198–205
Mackenzie L, Bootman MD, Laine M et al (2004) The role of inositol 1,4,5-trisphosphate receptors in Ca2+ signaling and the generation of arrhythmias in rat atrial myocytes. J Physiol 555:395–409
Zima AV, Blatter LA (2004) Inositol 1,4,5-trisphosphate-dependent Ca2+ signaling in cat atrial excitation-contraction coupling and arrhythmias. J Physiol 555:607–615
Ruiz-Hurtado G, Morel E, Dominguez-Rodriguez A et al (2013) Epac in cardiac calcium signaling. J Mol Cell Cardiol 58:162–171
Pereira L, Ruiz-Hurtado G, Morel E et al (2012) Epac enhances excitation-transcription coupling in cardiac myocytes. J Mol Cell Cardiol 52:283–291
Lin F, Owens WA, Chen S et al (2001) Targeted α1B-adrenergic receptor overexpression induces enhanced cardiac contractility but not hypertrophy. Circ Res 89:343–350
Milano CA, Dolber PC, Rockman HA et al (1994) Myocardial expression of a constitutively active 1β-adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc Natl Acad Sci U S A 91:10109–10113
Arthur JF, Matkovich SJ, Mitchell CJ et al (2001) Evidence for selective coupling of α1-adrenergic receptors to phospholipase C-β1 in rat neonatal cardiomyocytes. J Biol Chem 276:37341–37346
Grubb DR, Vasilevski O, Huynh H, Woodcock EA (2008) The extreme C-terminal region of phospholipase C β1 determines subcellular localization and function; the “b” splice variant mediates α1-adrenergic receptor responses in cardiomyocytes. FASEB J 22:2768–2774
Kawaguchi H, Sano H, Iizuka K et al (1993) Phosphatidylinositol metabolism in hypertrophic rat heart. Circ Res 72:966–972
Shoki M, Kawaguchi H, Okamoto H et al (1992) Phosphatidylinositol and inositolphosphatide metabolism in hypertrophied rat heart. Jpn Circ J 56:142–147
Sakata Y (1993) Tissue factors contributing to cardiac hypertrophy in cardiomyopathic hamsters (BIO14.6): involvement of transforming growth factor-beta 1 and tissue renin-angiotensin system in the progression of cardiac hypertrophy. Hokkaido Igaku Zasshi 68:18–28
Dent MR, Dhalla NS, Tappia PS (2004) Phospholipase C gene expression, protein content and activities in cardiac hypertrophy and heart failure due to volume overload. Am J Physiol Heart Circ Physiol 282:H719–H727
Dent MR, Aroutiounova N, Dhalla NS, Tappia PS (2006) Losartan attenuates phospholipase C isozyme gene expression in hypertrophied hearts due to volume overload. J Cell Mol Med 10:470–479
Jalili T, Takeishi Y, Song G et al (1999) PKC translocation without changes in Gαq and PLC-β protein abundance in cardiac hypertrophy and failure. Am J Physiol Heart Circ Physiol 277:H2298–H2304
Bai H, Wu LL, Xing DQ, Liu J, Zhao YL (2004) Angiotensin II induced upregulation of Gαq/11, phospholipase C β3 and extracellular signal-regulated kinase 1/2 via angiotensin II type 1 receptor. Chin Med J 117:88–93
Giles TD, Sander GE, Thomas MG, Quiroz AC (1986) α-adrenergic mechanisms in the pathophysiology of left ventricular heart failure—an analysis of their role in systolic and diastolic dysfunction. J Mol Cell Cardiol 18:33–43
Prasad K, O’Neil CL, Bharadwaj B (1984) Effect of prolonged prazosin treatment on hemodynamic and biochemical changes in the dog heart due to chronic pressure overload. Jpn Heart J 25:461–476
Motz W, Klepzig M, Strauer BE (1987) Regression of cardiac hypertrophy: experimental and clinical results. J Cardiovasc Pharmacol 10:S148–S152
Zakynthinos E, Pierrutsakos CH, Daniil Z, Papadogiannis D (2005) Losartan controlled blood pressure and reduced left ventricular hypertrophy but did not alter arrhythmias in hypertensive men with preserved systolic function. Angiology 56:439–449
Kanno Y, Kaneko K, Kaneko M et al (2004) Angiotensin receptor antagonist regresses left ventricular hypertrophy associated with diabetic nephropathy in dialysis patients. J Cardiovasc Pharmacol 43:380–386
Ruzicka M, Yuan B, Leenen FH (1994) Effects of enalapril versus losartan on regression of volume overload-induced cardiac hypertrophy in rats. Circulation 90:484–491
Rothermund L, Vetter R, Dieterich M et al (2002) Endothelin-A receptor blockade prevents left ventricular hypertrophy and dysfunction in salt-sensitive experimental hypertension. Circulation 106:2305–2308
Yamamoto K, Masuyama T, Sakata Y et al (2002) Prevention of diastolic heart failure by endothelin type A receptor antagonist through inhibition of ventricular structural remodeling in hypertensive heart. J Hypertens 20:753–761
Lund AK, Goens MB, Nunez BA, Walker MK (2006) Characterizing the role of endothelin-1 in the progression of cardiac hypertrophy in aryl hydrocarbon receptor (AhR) null mice. Toxicol Appl Pharmacol 212:127–135
Ruwhof C, van Wamel JT, Noordzij LA et al (2001) Mechanical stress stimulates phospholipase C activity and intracellular calcium ion levels in neonatal cardiomyocytes. Cell Calcium 29:73–83
Barac YD, Zeevi-Levin N, Yaniv G et al (2005) The 1,4,5-inositol trisphosphate pathway is a key component in Fas-mediated hypertrophy in neonatal rat ventricular myocytes. Cardiovasc Res 68:75–86
D’Angelo DD, Sakata Y, Lorenz JN et al (1997) Transgenic Gαq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci U S A 94:8121–8126
Sakata Y, Hoit BD, Liggett SB et al (1998) Decompensation of pressure-overload hypertrophy in Gαq-overexpressing mice. Circulation 97:1488–1495
Adams JW, Sakata Y, Davis MG et al (1998) Enhanced Gαq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci U S A 95:10140–10145
Sussman MA, Welch S, Walker A et al (2000) Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active rac1. J Clin Invest 105:875–886
Paradis P, Dali-Youcef N, Paradis FW, Thibault G, Nemer M (2000) Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci U S A 97:931–936
Mende U, Kagen A, Cohen A et al (1998) Transient cardiac expression of constitutively active Gαq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. Proc Natl Acad Sci U S A 95:13893–13898
Mende U, Kagen A, Meister M, Neer EJ (1999) Signal transduction in atria and ventricles of mice with transient cardiac expression of activated G protein alpha(q). Circ Res 85:1085–1091
Mende U, Semsarian C, Martins DC et al (2001) Dilated cardiomyopathy in two transgenic mouse lines expressing activated G protein αq: lack of correlation between phospholipase C activation and the phenotype. J Mol Cell Cardiol 33:1477–1491
Hollinger S, Hepler JR (2002) Cellular regulation of RGS proteins: modulators and integrators of G protein signaling. Pharmacol Rev 54:527–559
Anger T, Zhang W, Mende U (2004) Differential contribution of GTPase activation and effector antagonism to the inhibitory effect of RGS proteins on Gq-mediated signaling in vivo. J Biol Chem 279:3906–3915
Zhang W, Anger T, Su J et al (2006) Selective loss of fine tuning of Gq/11 signaling by RGS2 protein exacerbates cardiomyocyte hypertrophy. J Biol Chem 281:5811–5820
Park-Windhol C, Zhang P, Zhu M et al (2012) Gq/11-mediated signaling and hypertrophy in mice with cardiac-specific transgenic expression of regulator of G-protein signaling 2. PLoS One 7:e40048
Dhalla NS, Xu Y-J, Sheu S-S et al (1997) Phosphatidic acid: a potential signal transducer for cardiac hypertrophy. J Mol Cell Cardiol 29:2865–2871
Zhang L, Malik S, Kelley GG et al (2011) Phospholipase C epsilon scaffolds to muscle-specific A kinase anchoring protein (mAKAPbeta) and integrates multiple hypertrophic stimuli in cardiac myocytes. J Biol Chem 286:23012–23021
Zhang L, Malik S, Pang J et al (2013) Phospholipase Cε hydrolyzes perinuclear phosphatidylinositol 4-phosphate to regulate cardiac hypertrophy. Cell 153:216–227
Small K, Feng JF, Lorenz J et al (1999) Cardiac specific overexpression of transglutaminase II (Gh) results in a unique hypertrophy phenotype independent of phospholipase C activation. J Biol Chem 23:21291–21296
Morris JB, Huynh H, Vasilevski O, Woodcock EA (2006) α1-Adrenergic receptor signaling is localized to caveolae in neonatal rat cardiomyocytes. J Mol Cell Cardiol 41:117–125
Barka T, van der Noen H, Shaw PA (1987) Proto-oncogene fos (c-fos) expression in the heart. Oncogene 1:439–443
Hannan RD, West AK (1991) Adrenergic agents, but not triiodo-L-thyronine induce c-fos and c-myc expression in the rat heart. Basic Res Cardiol 86:154–164
Iwaki K, Sukhatme VP, Shubeita HE, Chien KR (1990) α- and β-adrenergic stimulation induces distinct patterns of immediate early gene expression in neonatal rat myocardial cells. fos/jun expression is associated with sarcomere assembly; Egr-1 induction is primarily an α1-mediated response. J Biol Chem 265:13809–13817
Komuro I, Kaida T, Shibazaki Y et al (1990) Stretching cardiac myocytes stimulates protooncogene expression. J Biol Chem 265:3595–3598
Gutkind JS (1998) The pathway connecting G protein-coupled receptors to the nucleus through divergent mitogen-activated protein kinase cascades. J Biol Chem 273:1839–1842
Chiu R, Boyle WJ, Meek J et al (1988) The c-Fos protein interacts with c-Jun/AP-1 to stimulate transcription of AP-1 responsive genes. Cell 54:541–552
Lijnen P, Petrov V (1999) Antagonism of the renin-angiotensin system, hypertrophy and gene expression in cardiac myocytes. Methods Find Exp Clin Pharmacol 21:363–374
Singal T, Dhalla NS, Tappia PS (2010) Reciprocal regulation of transcription factors and PLC isozyme gene expression in adult cardiomyocytes. J Cell Mol Med 14:1824–1835
Singal T, Dhalla NS, Tappia PS (2009) Regulation of c-Fos and c-Jun gene expression by phospholipase C activity in adult cardiomyocytes. Mol Cell Biochem 327:229–239
Otaegui D, Querejeta R, Arrieta A et al (2010) Phospholipase Cβ4 isozyme is expressed in human, rat and murine heart left ventricles and HL-1 cardiomyocytes. Mol Cell Biochem 337:167–173
Strauer BE, Bayer F, Brecht HM, Motz W (1985) The influence of sympathetic nervous activity on regression of cardiac hypertrophy. J Hypertens 3:S39–S44
Strauer BE (1995) Progression and regression of heart hypertrophy in arterial hypertension: pathophysiology and clinical aspects. Z Kardiol 74:171–178
Strauer BE (1988) Regression of myocardial and coronary vascular hypertrophy in hypertensive heart disease. J Cardiovasc Pharmacol 12:S45–S54
Acknowledgment
Infrastructural support was provided by the St. Boniface Hospital Research Foundation.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Tappia, P.S., Dhalla, N.S. (2014). Activation of Phospholipase C in Cardiac Hypertrophy. In: Tappia, P., Dhalla, N. (eds) Phospholipases in Health and Disease. Advances in Biochemistry in Health and Disease, vol 10. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0464-8_18
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0464-8_18
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-0463-1
Online ISBN: 978-1-4939-0464-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)